# Evvy

> At-home CLIA/CLEP mNGS vaginal microbiome tests plus clinician-guided care.

## Why it is interesting

On Sep 15, 2026 Evvy raised a $40M Series B led by Catalio on a company-claimed 100,000+ patient dataset — expanding from vaginal health into fertility research without disclosing valuation.

## Profile

- **Latest funding:** Series B — $40M (September 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $40M
- **Stage:** series-b
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-10-29
- **Latest funding investors:** Catalio Capital Management, Alumni Ventures, Rethink Impact, Muse Capital

## Key facts

- $40M Series B led by Catalio Capital Management (Sep 15, 2026)
- >100,000 patients and ~3,000 practitioners claimed (TechCrunch)
- Expanding research toward fertility / IVF-adjacent microbiome links

## Funding history

- Series B · $40M · September 2026
  Source: https://www.mobihealthnews.com/news/evvy-raises-40m-expand-vaginal-microbiome-platform

## Investors in our directory

- https://venturecapitaltracker.com/fund/alumni-ventures

## Related articles

- https://venturecapitaltracker.com/2026-evvy-40m-series-b-catalio-womens-health
- https://venturecapitaltracker.com/2026-september-15-16-investment-news-factory-profound-thatch

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 29, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/evvy